Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunpeng Fan

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Journal of Allergy and Clinical Immunology|March 2, 2024
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trialsMarcus Maurer, Thomas B Casale, Sarbjit S Saini, et al.
Obesity (Silver Spring, Md.)|July 30, 2011
The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in miceZhen Pang, Nancy N Wu, Weiguang Zhao, et al.
Lancet (London, England)|September 24, 2019
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsClaus Bachert, Joseph K Han, Martin Desrosiers, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Journal of Allergy and Clinical Immunology|March 2, 2024
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trialsMarcus Maurer, Thomas B Casale, Sarbjit S Saini, et al.
Obesity (Silver Spring, Md.)|July 30, 2011
The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in miceZhen Pang, Nancy N Wu, Weiguang Zhao, et al.
Lancet (London, England)|September 24, 2019
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsClaus Bachert, Joseph K Han, Martin Desrosiers, et al.
Pageof 3